Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • CytRx Corp. (CYTR) Featured In Bullish Seeking Alpha Article 0 comments
    Dec 26, 2013 5:35 PM | about stocks: CYTR

    CytRx, a biopharm research and development company specializing in the development of drug candidates for the field of oncology, was recently covered in an article by Seeking Alpha contributor U.S. Biotech Investor, who reviews data from the company's recent phase 2b clinical trial data before issuing a bullish stance on the company's stock.

    To read the entire article visit seekingalpha.com/instablog/15280302-u-s-...-winner

    Aldoxorubicin is an improved formulation of doxorubicin, a widely used but highly toxic chemotherapy agent. CytRx recently released interim clinical data from a phase 2b trial in which aldoxorubicin demonstrated superiority to doxorubicin as first-line treatment of soft tissue sarcomas (NYSEMKT:STS). Results showed that patients administered aldoxorubicin were able to tolerate 3.5 times the standard dose of doxorubicin with fewer side effects, resulting in greater positive response to treatment.

    "If trials continue as successfully as they have, Investors should see aldoxorubicin take the place of doxorubicin. CytRx Corporation will also find an immediate market with a monstrous revenue stream," writes U.S. Biotech Investor.

    The article also recaps words from CytRx CEO Steven Kriegsman, who is quoted as saying that aldoxorubicin's underlying linker technology "has broad potential utility with proven affinity to couple with multiple chemotherapeutic agents including paclitaxel, docetaxel, cisplatin, irinotecan and methotrexate. Each of these agents may be incorporated into our future clinical development plans."

    A brief summary of CytRx precedes the author's conclusion that:

    "CytRx Corporation shares are in the start of a per share revaluation. The reset forming is due to solid data released on a coming best in class cancer treatment targeting soft-tissue sarcoma. The recent profit taking that occurred after favorable data release spiked the share price has created an attractive entry point. The savvy investor is now buying a position in Cytrx having had the patience to wait out profit taking."

    For more information visit cytrx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.